<div id="readability-page-1"><div> By Josh Beckerman <pre></pre> Broadwood Partners, which owns 27.3% of Staar Surgical, said it intends to vote against the lens company's sale to Alcon, citing issues related to the sale process and its belief in Staar's growth potential. Broadwood said Tuesday that Staar didn't pursue an adequate sale process and there was &#34;intransigence with respect to the process regarding Broadwood's books and records demand.&#34; Staar said the deal provides &#34;compelling, premium cash value,&#34; including a 51% premium to its Aug. 4 closing price. &#34;We believe the $28-per-share cash value provided by the Alcon agreement exceeds what STAAR could achieve on a standalone basis in the foreseeable future, particularly given STAAR's lower growth rate and the resulting impact on its valuation, and the substantial competitive and macro challenges in the markets STAAR serves,&#34; the company said. &#34;STAAR is heavily exposed to China, which faces significant economic uncertainty and where sales trends have been declining despite actions taken by the company,&#34; Staar said. The Alcon deal includes provisions that are highly favorable to Staar stockholders and were extensively negotiated, it said. <pre></pre> Write to Josh Beckerman at josh.beckerman@wsj.com <pre></pre> (END) Dow Jones Newswires September 02, 2025 19:07 ET (23:07 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

愛爾康

達視光學

Broadwood Partners 持有達視光學 27.3% 的股份，計劃投票反對該公司出售給愛爾康，理由是對出售過程和達視光學的增長潛力表示擔憂。他們認為達視光學沒有充分追求出售，並且在獲取記錄方面面臨問題。達視光學為這筆交易辯護，強調其最近收盤價的 51% 溢價，並聲稱每股 28 美元的報價超過了潛在的獨立價值，儘管市場面臨挑戰，特別是在中國

Broadwood Partners Plans to Vote Against Staar Sale to Alcon